MDACC Study No:2013-0873 ( NCT No: NCT01993641)
Title:A Phase II Simon Two-Stage Study of the Addition of Pracinostat to a Hypomethylating Agent (HMA) in Patients with Myelodysplastic Syndrome (MDS) Who Have Failed to Respond or Maintain a Response to the HMA Alone
Principal Investigator:Guillermo Garcia-Manero
Treatment Agent:Azacitidine; Decitabine; Pracinostat
Study Status:Closed
Study Description:The goal of this clinical research study is to learn if adding pracinostat to
the drug that you have already received (azacitidine or decitabine) can help to
control MDS. The safety of this drug combination will also be studied.

The main part of the study has completed. However, an extension phase has been
added to this study to allow patients already receiving pracinostat to continue
to receive pracinostat if they/their study doctor feel they are benefitting
from treatment with pracinostat + azacitidine or decitabine. You are being
invited to take part in this extension phase.
Hide details for General InformationGeneral Information

Disease Group:Leukemia
Phase of Study:Phase II
Treatment Agents:Azacitidine
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:MEI Pharma, Inc.
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Guillermo Garcia-Manero
For Clinical Trial Enrollment:713-745-3428
For General Questions about Clinical Trials:1-877-MDA-6789

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults